Glaukos Corporation Files Registration Statement for Proposed Initial Public Offering
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation, an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering (IPO) of its common stock. The number of shares to be offered and the price range for the
